Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Analysis of Short-term (Operating) Activity Ratios

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Short-term Activity Ratios (Summary)

AbbVie Inc., short-term (operating) activity ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Turnover Ratios
Inventory turnover
Receivables turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Add: Average receivable collection period
Operating cycle
Less: Average payables payment period
Cash conversion cycle

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


An examination of short-term operating activity ratios reveals several noteworthy trends between 2021 and 2025. Generally, a declining trend is observed in efficiency metrics related to inventory and receivables, while payables turnover remains relatively stable. These shifts are reflected in lengthening processing and conversion cycles.

Inventory Management
Inventory turnover decreased consistently from 5.58 in 2021 to 3.68 in 2025. This indicates a growing inefficiency in managing inventory, suggesting either overstocking or slower sales. Correspondingly, the average inventory processing period lengthened from 65 days in 2021 to 99 days in 2025, confirming that inventory is taking longer to convert into sales. This increase could tie to changes in product mix, supply chain disruptions, or weakening demand.
Receivables Management
Receivables turnover exhibited a slight decline, moving from 5.63 in 2021 to 4.86 in 2025. While not as dramatic as the inventory trend, this suggests a gradual slowdown in collecting receivables. The average receivable collection period increased from 65 days to 75 days over the same period, reinforcing the observation of slower collections. This could be attributable to extended credit terms offered to customers or a rise in uncollectible accounts.
Payables Management
Payables turnover showed relative stability, fluctuating between 5.07 and 6.05 over the five-year period. The average payables payment period increased from 60 days in 2021 to 72 days in 2025, indicating a trend towards taking longer to settle obligations with suppliers. This could be a strategic decision to preserve cash flow, but should be monitored to avoid damaging supplier relationships.
Operating and Cash Cycles
The operating cycle lengthened from 130 days in 2021 to 174 days in 2025, reflecting the combined effect of slower inventory turnover and receivable collection. The cash conversion cycle also increased, moving from 70 days to 102 days over the same period. This indicates that the company is taking longer to convert its investments in inventory and receivables into cash, potentially impacting liquidity.

In summary, the observed trends suggest a gradual decrease in the efficiency of working capital management. The lengthening of processing and conversion cycles warrants further investigation to identify the underlying causes and implement corrective actions.


Turnover Ratios


Average No. Days


Inventory Turnover

AbbVie Inc., inventory turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cost of products sold
Inventories
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Inventory Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Inventory Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Inventory turnover = Cost of products sold ÷ Inventories
= ÷ =

2 Click competitor name to see calculations.


The inventory turnover ratio demonstrates a declining trend over the five-year period. While cost of products sold fluctuated, inventories consistently increased, contributing to this decrease in turnover.

Inventory Turnover Trend
The inventory turnover ratio decreased from 5.58 in 2021 to 3.68 in 2025. This indicates a lengthening of the average time it takes to sell inventory. The most significant decline occurred between 2023 and 2025.
Cost of Products Sold
Cost of products sold experienced a moderate increase from 2021 to 2023, rising from US$17,446 million to US$20,415 million. However, it then decreased in 2024 to US$16,904 million before increasing slightly to US$18,204 million in 2025. This fluctuation in cost of goods sold does not fully explain the consistent decline in inventory turnover.
Inventory Levels
Inventories exhibited a consistent upward trend, increasing from US$3,128 million in 2021 to US$4,951 million in 2025. This continuous growth in inventory levels, coupled with the fluctuating cost of products sold, is the primary driver of the declining inventory turnover ratio. The largest increase in inventory occurred between 2024 and 2025.

The observed trend suggests a potential inefficiency in inventory management. Further investigation may be warranted to understand the reasons behind the increasing inventory levels and the impact on working capital.


Receivables Turnover

AbbVie Inc., receivables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Net revenues
Accounts receivable, net
Short-term Activity Ratio
Receivables turnover1
Benchmarks
Receivables Turnover, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Receivables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Receivables Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Receivables turnover = Net revenues ÷ Accounts receivable, net
= ÷ =

2 Click competitor name to see calculations.


The receivables turnover ratio exhibited a generally declining trend over the five-year period, with some fluctuation. Net revenues also demonstrated variability, impacting the interpretation of the receivables turnover. Accounts receivable, net, increased initially before stabilizing and then increasing again in the final year.

Receivables Turnover Trend
The receivables turnover ratio decreased from 5.63 in 2021 to 5.16 in 2022, representing a reduction in the efficiency of converting receivables into cash. A further decline to 4.87 was observed in 2023. The ratio experienced a slight recovery to 5.16 in 2024, but then decreased again to 4.86 in 2025, indicating a continued, albeit moderate, weakening in the collection of receivables.
Relationship to Net Revenues
Net revenues increased from US$56,197 million in 2021 to US$58,054 million in 2022. However, the receivables turnover decreased during this period, suggesting that the increase in sales was accompanied by a slower collection of receivables. Revenues decreased in 2023 to US$54,318 million, coinciding with a further drop in the turnover ratio. A subsequent revenue increase to US$56,334 million in 2024 did not fully translate into an improved turnover ratio. The largest revenue increase occurred in 2025, reaching US$61,160 million, but the receivables turnover continued to decline.
Accounts Receivable, Net
Accounts receivable, net, increased from US$9,977 million in 2021 to US$11,254 million in 2022. This increase, coupled with the decrease in receivables turnover, suggests a lengthening of the collection period. The balance remained relatively stable at US$11,155 million in 2023 and US$10,919 million in 2024. A notable increase to US$12,589 million was observed in 2025, which, combined with the lowest turnover ratio of the period, indicates a potential issue with collecting receivables efficiently as sales increased.

The combined trends suggest that while the company experienced revenue fluctuations, its ability to efficiently manage and collect receivables has generally weakened over the observed period. The increase in accounts receivable in the final year, alongside a declining turnover ratio, warrants further investigation.


Payables Turnover

AbbVie Inc., payables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cost of products sold
Accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Payables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Payables Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Payables turnover = Cost of products sold ÷ Accounts payable
= ÷ =

2 Click competitor name to see calculations.


The accounts payable turnover ratio exhibited a generally decreasing trend over the five-year period. While fluctuations occurred, the overall movement suggests a lengthening of the time it takes the company to pay its suppliers.

Payables Turnover Trend
The payables turnover ratio began at 6.05 in 2021, decreased to 5.94 in 2022, and continued to decline to 5.54 in 2023. A slight recovery was observed in 2024, with the ratio increasing to 5.74. However, this was followed by a further decrease to 5.07 in 2025, representing the lowest value within the observed period.

The cost of products sold demonstrated variability during the period. It remained relatively stable between 2021 and 2022, increased significantly in 2023, decreased in 2024, and then increased again in 2025. This fluctuation in cost of goods sold may influence the interpretation of the payables turnover ratio.

Accounts Payable Trend
Accounts payable increased from US$2,882 million in 2021 to US$2,934 million in 2022. A more substantial increase was noted in 2023, reaching US$3,688 million. This was followed by a decrease to US$2,945 million in 2024, and a subsequent increase to US$3,592 million in 2025. The increase in accounts payable, coupled with the decreasing turnover ratio, suggests the company is utilizing more credit from its suppliers and taking longer to settle those obligations.

The combined effect of the decreasing payables turnover ratio and the fluctuating accounts payable levels indicates a potential shift in the company’s payment practices or a change in supplier terms. Further investigation into the company’s credit policies and supplier relationships would be necessary to fully understand these trends.


Working Capital Turnover

AbbVie Inc., working capital turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Current assets
Less: Current liabilities
Working capital
 
Net revenues
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Working Capital Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Working Capital Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Working capital turnover = Net revenues ÷ Working capital
= ÷ =

2 Click competitor name to see calculations.


The analysis reveals a fluctuating pattern in working capital alongside increasing net revenues over the five-year period. Working capital is consistently negative, indicating that current liabilities exceed current assets. The working capital turnover ratio, calculated from these figures, demonstrates a significant trend over time.

Working Capital
Working capital begins at negative US$7,266 million in 2021, improves to negative US$1,075 million in 2022, then deteriorates to negative US$4,839 million in 2023. Further declines are observed in 2024 and 2025, reaching negative US$13,167 million and negative US$14,227 million respectively. This consistent negativity, and the increasing magnitude of the negative balance, suggests a growing reliance on short-term financing to fund operations.
Net Revenues
Net revenues exhibit an overall upward trend. Revenues increase from US$56,197 million in 2021 to US$58,054 million in 2022, experience a slight decrease to US$54,318 million in 2023, and then rise to US$56,334 million in 2024. A more substantial increase is seen in 2025, with revenues reaching US$61,160 million. This indicates a general growth in sales despite the negative working capital position.
Working Capital Turnover
Given the provided working capital and net revenue figures, the working capital turnover can be calculated. For 2021, the ratio is 56,197 / -7,266 = -7.73. In 2022, it is 58,054 / -1,075 = -54.00. For 2023, the ratio is 54,318 / -4,839 = -11.23. In 2024, it is 56,334 / -13,167 = -4.28. Finally, in 2025, the ratio is 61,160 / -14,227 = -4.29. The turnover ratio is negative in all periods due to the negative working capital. The absolute value of the ratio decreases from 2021 to 2024, then stabilizes. This suggests that while the company generates revenue from its working capital, the efficiency of this process, as measured by the turnover ratio, has decreased initially, then remained relatively constant. The decreasing absolute value implies that a larger amount of working capital (in absolute terms) is required to generate each dollar of revenue.

The combination of negative and declining working capital alongside increasing revenues suggests the company is effectively managing its sales despite a challenging short-term financial position. However, the continued reliance on negative working capital warrants further investigation into the company’s financing strategies and liquidity management.


Average Inventory Processing Period

AbbVie Inc., average inventory processing period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Average Inventory Processing Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Average Inventory Processing Period, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


An examination of the provided financial information reveals a consistent lengthening of the average inventory processing period alongside a declining inventory turnover ratio over the five-year period. These trends suggest a potential slowdown in the efficiency of inventory management.

Inventory Turnover
The inventory turnover ratio decreased from 5.58 in 2021 to 3.68 in 2025. This indicates that inventory is being sold more slowly over time. The most significant decline occurred between 2022 and 2024, with a more moderate decrease observed between 2024 and 2025. A lower turnover ratio can imply overstocking, obsolescence, or a weakening in sales.
Average Inventory Processing Period
The average inventory processing period increased steadily from 65 days in 2021 to 99 days in 2025. This signifies that it is taking progressively longer to convert inventory into sales. The increase was relatively consistent year-over-year, with a slightly larger increase from 2023 to 2024, reaching 90 days, and continuing to 99 days in the most recent year. A lengthening processing period corroborates the declining inventory turnover and suggests potential inefficiencies in the supply chain or inventory control processes.

The concurrent movement of these two ratios points to a consistent pattern. The increasing time required to process inventory directly contributes to the decreasing rate at which inventory is turned over. Further investigation into the underlying causes of these trends, such as changes in product mix, demand fluctuations, or supply chain disruptions, would be beneficial.


Average Receivable Collection Period

AbbVie Inc., average receivable collection period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Receivables turnover
Short-term Activity Ratio (no. days)
Average receivable collection period1
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Average Receivable Collection Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Average Receivable Collection Period, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The average receivable collection period exhibited an increasing trend over the observed period, with some stabilization in later years. Analysis of the receivables turnover ratio reveals a corresponding pattern, providing context to the changes in collection period.

Average Receivable Collection Period
The average receivable collection period increased from 65 days in 2021 to 71 days in 2022. This upward trend continued into 2023, reaching 75 days. The period then decreased slightly to 71 days in 2024, before returning to 75 days in 2025. This suggests a potential lengthening in the time required to collect receivables, followed by a minor improvement, and then a return to the longer collection timeframe.
Receivables Turnover
The receivables turnover ratio decreased from 5.63 in 2021 to 5.16 in 2022. A further decline was observed in 2023, reaching 4.87. The ratio experienced a slight recovery to 5.16 in 2024, but decreased again to 4.86 in 2025. This decreasing trend in receivables turnover directly correlates with the increasing average collection period, indicating that the company is collecting receivables less frequently over time.

The consistency of the 75-day collection period in both 2023 and 2025 suggests a potential stabilization at this level, although further monitoring is warranted to confirm this. The initial increase in the collection period, coupled with the declining turnover ratio, may warrant investigation into the company’s credit policies and collection efforts.


Operating Cycle

AbbVie Inc., operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Average inventory processing period
Average receivable collection period
Short-term Activity Ratio
Operating cycle1
Benchmarks
Operating Cycle, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Operating Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Operating Cycle, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =

2 Click competitor name to see calculations.


An examination of the short-term operating activity reveals a consistent lengthening of the operating cycle over the five-year period. Each component contributing to the operating cycle – average inventory processing period and average receivable collection period – demonstrates an increasing trend, contributing to the overall extended cycle duration.

Average Inventory Processing Period
The average inventory processing period increased from 65 days in 2021 to 99 days in 2025. This represents a 52.3% increase over the period. The increase was not linear, with a jump from 73 days in 2023 to 90 days in 2024. This suggests potential inefficiencies in inventory management or a shift in inventory composition towards slower-moving items.
Average Receivable Collection Period
The average receivable collection period also exhibited an upward trend, rising from 65 days in 2021 to 75 days in 2025. This represents a 15.4% increase. The increase was relatively steady, with a slight dip in 2024 to 71 days before returning to 75 days in 2025. This could indicate a loosening of credit terms, a change in customer mix, or difficulties in collecting receivables.
Operating Cycle
The operating cycle, calculated as the sum of the average inventory processing period and the average receivable collection period, increased from 130 days in 2021 to 174 days in 2025. This 33.8% increase signifies that it is taking progressively longer to convert investments in inventory and receivables into cash. The most significant increase occurred between 2023 and 2025, mirroring the accelerated increases observed in both inventory processing and receivable collection periods.

The concurrent increases in both inventory processing and receivable collection periods suggest a systemic issue impacting the efficiency of working capital management. Further investigation is warranted to determine the underlying causes of these trends and to assess their potential impact on liquidity and profitability.


Average Payables Payment Period

AbbVie Inc., average payables payment period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Average Payables Payment Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Average Payables Payment Period, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


An examination of the short-term activity ratios reveals a consistent trend in the average payables payment period over the five-year period. The payables turnover ratio demonstrates a generally decreasing pattern, while the average payables payment period correspondingly increases.

Payables Turnover
The payables turnover ratio decreased from 6.05 in 2021 to 5.07 in 2025. While there was a slight increase from 5.54 in 2023 to 5.74 in 2024, the overall trend is downward, indicating a slowing in the rate at which the company pays its suppliers. The most significant decline occurred between 2022 and 2023, and again between 2024 and 2025.
Average Payables Payment Period
The average payables payment period exhibited an increasing trend, rising from 60 days in 2021 to 72 days in 2025. This increase aligns with the decreasing payables turnover ratio. A relatively stable period was observed between 2021 and 2022 (60 to 61 days), followed by a more pronounced increase to 66 days in 2023, a slight decrease to 64 days in 2024, and then a further increase to 72 days in 2025. This suggests a lengthening of the time taken to settle obligations to suppliers.
Overall Interpretation
The combined trends suggest the company is taking longer to pay its suppliers. This could be due to a variety of factors, including negotiating extended payment terms with suppliers, a deliberate strategy to manage cash flow, or potentially, increasing difficulty in meeting payment obligations. Further investigation would be required to determine the underlying cause of these changes.

Cash Conversion Cycle

AbbVie Inc., cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Average inventory processing period
Average receivable collection period
Average payables payment period
Short-term Activity Ratio
Cash conversion cycle1
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Cash Conversion Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Cash Conversion Cycle, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + =

2 Click competitor name to see calculations.


An examination of short-term operating activity reveals lengthening cycles across key components from 2021 to 2025. The average inventory processing period, receivable collection period, and payables payment period all demonstrate increases over the five-year timeframe, contributing to an extended cash conversion cycle.

Average Inventory Processing Period
The average inventory processing period increased from 65 days in 2021 to 99 days in 2025. This represents a 52% increase over the period, suggesting a growing inefficiency in managing inventory or a shift towards holding higher levels of stock. A slight dip was observed between 2022 and 2023, but the trend resumed upward in subsequent years.
Average Receivable Collection Period
The average receivable collection period also exhibited an upward trend, rising from 65 days in 2021 to 75 days in 2025. This indicates a lengthening of the time required to collect payments from customers. While the increase is less pronounced than that of the inventory processing period, it still contributes to a slower cash conversion cycle. The collection period remained stable between 2023 and 2024.
Average Payables Payment Period
The average payables payment period increased from 60 days in 2021 to 72 days in 2025. This suggests a lengthening of the time taken to pay suppliers. The increase, while present, is comparatively smaller than the increases observed in inventory and receivables. The period experienced minimal change between 2021 and 2022.
Cash Conversion Cycle
The cash conversion cycle lengthened considerably, increasing from 70 days in 2021 to 102 days in 2025. This signifies that it takes progressively longer to convert investments in inventory and other resources into cash flows. The cycle increased each year, with the most substantial increase occurring between 2023 and 2024. The combined effect of increasing inventory processing and receivable collection periods, partially offset by a slower increase in the payables payment period, drives this overall lengthening.

The consistent increases in these ratios suggest a potential need to review operational efficiencies related to inventory management, credit policies, and supplier negotiations. Further investigation is warranted to understand the underlying causes of these trends and their potential impact on liquidity and overall financial performance.